Actovegin

Deproteinized calf-blood extract

Actovegin (Deproteinized calf-blood extract) is a healing & recovery research compound. Improves cellular oxygen and glucose uptake — used to accelerate soft-tissue and muscle recovery.

How Actovegin works

Improves cellular oxygen and glucose uptake — used to accelerate soft-tissue and muscle recovery.

Proposed benefits

Researched for soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.

Where to get Actovegin

The evidence for Actovegin

Graded by what exists behind each claim.

✅ Clinically validated

• Registered as a medicine in Russia, Austria and several other countries, with randomized trials supporting use in diabetic polyneuropathy — a multicentre trial reported improved neuropathic symptoms against placebo.
• Not approved in the US or UK. Its reputation in sports medicine comes largely from use in elite football rather than from trial data for that purpose.

📊 Correlative data

• Long clinical use in central and eastern Europe, and well-documented use by sports physicians for muscle injury recovery — including the high-profile cases that brought it to attention.
• It is a calf-blood extract, not a defined molecule, which is the structural weakness in all of it: batch composition varies, and WADA has restricted the intravenous route.

🧪 Theoretical / extrapolated

• A deproteinized hemodialysate of calf blood, containing low-molecular-weight peptides, amino acids and oligosaccharides. Proposed to improve cellular glucose and oxygen utilization.
• Being an extract rather than a compound is the honest caveat on every claim here — you cannot fully characterize the mechanism of something whose contents are defined by a process rather than a formula.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Actovegin actually does

Start with what the label actually means. Deproteinized hemodialysate is not a description of a molecule, it is a description of a manufacturing step: calf blood is passed through an ultrafilter, everything above the cut-off is discarded, and whatever comes through is the product. The review written by the group closest to the drug puts the count at more than 200 biological substances Machicao 2012. There is no active ingredient named on this page because there is none named anywhere.

That same review contains the sentence nobody selling this quotes: because Actovegin is composed of small molecules that are already present under normal physiological conditions, pharmacokinetic and pharmacodynamic studies to identify its active substance are not feasible Machicao 2012. Read that twice. It is not a gap somebody has not got round to filling. It is a statement that the experiment cannot be designed, because you cannot measure a rise in something the body already makes and already has in the blood before you inject anything.

So what can be said at enzyme level? Three things, and each is a measurement rather than a claim. First, caspase-3: in primary rat neurons given amyloid-beta 25-35 to trigger apoptosis, Actovegin across 0.3–1,000 mg/L lowered activated caspase-3 in a dose-dependent way, raised total cell number and raised the count of excitatory synapses measured as V-Glut1 protein, while dendrite length was unchanged Elmlinger 2011. That last detail matters: the effect is on cell survival and synapse number, not on growth. Second, reactive oxygen species fell in the same cultures. Third, oxidative phosphorylation: high-resolution respirometry of vastus lateralis from streptozotocin-diabetic mice showed higher mitochondrial respiratory capacity in both ADP-restricted and ADP-stimulated states after dosing Kosik 2023.

The oxygen claim, made precise. Vendors say it improves oxygen utilization, and the phrase is usually read as if the product carried oxygen. It cannot: the ultrafiltration step that defines it removes hemoglobin along with every other protein. Whatever the effect is, it has to be downstream of delivery — at complex I to complex IV, or at the glucose transporters feeding them. The respirometry result Kosik 2023 is the only measurement that has actually looked at that step, and it was made in diabetic mouse muscle, not in a healthy athlete's.

Cell, rodent, human — and where it stops

In cell culture. Primary rat neurons, up to 10 days, 0.3–1,000 mg/L, apoptosis induced with amyloid-beta 25-35: activated caspase-3 down dose-dependently, cell number and synapse count up, ROS down Elmlinger 2011. Note the unit — mg/L of an undefined mixture. There is no molar concentration because there is no molecule.

In rodents. Streptozotocin type 1 diabetic male C57Bl/6 mice, aged 3–4 months, 0.1 mL intraperitoneally every third day for 13 days against saline. Skeletal muscle OXPHOS capacity rose, the fall in treadmill aerobic capacity was smaller, and baseline body mass was better preserved; food and water intake did not differ Kosik 2023. The dose is 0.1 mL — a volume, not a mg/kg — which is the recurring problem with this product and not the authors' fault.

In humans, and here it is genuinely stronger than most things on this site. Ziegler 2009 randomized 567 people with type 2 diabetes and symptomatic polyneuropathy to 20 daily intravenous infusions of 2,000 mg or placebo, then three tablets a day (1,800 mg/day) for 140 days. Total Symptom Score improved by 0.86 points from baseline at 160 days (95% CI 0.50–1.22; p<0.0001), vibration perception threshold by 5% (p=0.017), and adverse-event rates did not differ Ziegler 2009. ARTEMIDA randomized 503 people over 60 within a week of ischemic stroke to 2,000 mg/day intravenously for up to 20 infusions then 1,200 mg/day orally for 6 months; the ADAS-cog+ treatment difference at 6 months was −2.3 points (95% CI −3.9 to −0.7; p=0.005) Guekht 2017. APOLLO randomized 366 people with Fontaine stage IIB peripheral arterial disease across 19 centers to 1,200 mg/day intravenously for 2 weeks then orally for 10 weeks; initial claudication distance rose 29.19% at 12 weeks (p=0.0041) and 41.22 m in absolute terms at 24 weeks (p=0.0010) Suchkov 2022.

And then the sport question, which has now been asked directly and answered no. Milovanović 2024 is the trial this page exists to report: 16 moderately trained collegiate athletes, randomized double-blind to Actovegin or placebo, three capsules a day for seven days, with a maximal cardiopulmonary exercise test before and after. Peak oxygen uptake, peak minute ventilation, oxygen pulse, both ventilatory thresholds and peak velocity all improved — in both groups. The only time-by-group interaction was in systolic blood pressure (p=0.036). The authors' conclusion is that no benefit beyond placebo was attained Milovanović 2024.

The obstacles, and they are specific. (1) Every positive human trial ran a sequential intravenous-then-oral course of 1,200–2,000 mg/day for 12 to 24 weeks in tissue that was ischemic or denervated. Sport uses a handful of intramuscular injections into a healthy muscle around an acute injury. Not one trial has tested that schedule, that route or that population. (2) The only trial that did test athletes used 7 days of oral capsules and found nothing Milovanović 2024 — and 7 days of oral dosing is not the 20-infusion loading phase either, so the honest reading is that the regimens with evidence and the regimens people use do not overlap at any point. (3) The independent systematic review pooled 5 studies over 3,879 patients, of whom 720 received Actovegin, and found no consistent evidence of improved survival, quality of life, neurological symptoms, activities of daily living or disability — and one included study reported a higher incidence of recurrent ischemic stroke, transient ischemic attack or intracerebral hemorrhage on Actovegin than on placebo La Fleur 2022. (4) The mechanism work is in diabetic mouse muscle and amyloid-stressed rat neurons Kosik 2023 Elmlinger 2011; a healthy trained person's muscle is neither hypoxic nor apoptotic, so the substrate the mechanism acts on is largely absent.

Actovegin pharmacokinetics — how much of it actually gets in

The catalog says ‘Not defined (biological mixture)’. That is correct, and it is the most interesting fact on this page rather than a blank to apologize for.

Why a half-life cannot exist here. A half-life is a property of an analyte. You need one substance, one assay, one concentration curve. Actovegin is over 200 substances Machicao 2012, and they are amino acids, oligosaccharides, nucleosides and small peptides that a person already carries at millimolar to micromolar concentrations before the needle goes in. Even if you picked one and measured it, you would be measuring a small addition to a large endogenous pool with its own diurnal variation. That is why the manufacturer-aligned review states outright that identifying the active substance by pharmacokinetic study is not feasible Machicao 2012, and it is a more honest sentence than any number a vendor could print.

What degrades it, insofar as the question means anything at all. Split the mixture in two. The fraction that is short peptides meets exactly what every short peptide meets: plasma aminopeptidases on the injected route, and gastric acid, pancreatic proteases and brush-border peptidases on the oral one, so enzymatic hydrolysis reduces that fraction to free amino acids within minutes. The rest — amino acids, nucleosides, oligosaccharides — is not degraded in any drug sense; it is consumed, entering the same metabolic pools as a meal. So ‘what clears it’ has two answers, proteolysis and intermediary metabolism, and neither of them produces a concentration-time curve you could put a half-life on.

What could be measured instead, which is the part nobody writes. Three things, all of them cheap. (i) A batch fingerprint. An LC-MS profile of five lots against each other would put a number on lot-to-lot variability, which for a process-defined product is the only meaningful specification. No such comparison is published for any manufacturer. (ii) A residual-protein assay. ‘Deproteinized’ is the safety claim on the box; total protein and albumin in the vial is the number that tests it, and it is not on any certificate of analysis a buyer sees. (iii) A pharmacodynamic surrogate rather than a concentration. Kosik measured mitochondrial respiration instead of drug levels Kosik 2023; the human version is a mixed-meal glucose tolerance test or a muscle biopsy respirometry run before and after a course. Substitute the effect for the analyte when there is no analyte.

The oral barrier, inverted. For an ordinary drug the question is how much survives the gut and the first-pass liver. Here it runs backwards: if the actives really are small physiological molecules, they are absorbed by the ordinary nutrient transporters and become indistinguishable from food the moment they cross. That makes the 140-day oral phase of the Ziegler trial (1,800 mg/day of tablets) pharmacologically the hardest arm to explain, and it is also the arm that carried most of the exposure Ziegler 2009.

Route, and the number that catches athletes. Every trial used intravenous infusion first (2,000 mg/day in Ziegler and ARTEMIDA, 1,200 mg/day in APOLLO) and oral tablets after. This site lists it as intramuscular, which is what sports medicine uses and the route with zero controlled trial data. And the anti-doping rule that bites is about the method rather than the molecule: WADA prohibits intravenous infusions and/or injections of more than 100 mL per 12-hour period outside legitimate hospital treatment. The same vial can therefore be permitted by intramuscular injection and a violation by drip, which is a distinction most discussion of this product misses. Check the current Prohibited List rather than this paragraph before you compete.

What would have to be true, and how you would know it was not

Four predictions. The first is the one that has already been run, and it went against the product.

1. VO2 peak will not move in a trained person, and it did not. Milovanović loaded 16 collegiate athletes for 7 days and every cardiopulmonary variable improved equally on placebo Milovanović 2024. Prediction: repeat it at a higher dose or by injection and the answer stays no, because the mechanism that is actually documented — anti-apoptotic and mitochondrial rescue in ischemic or diabetic tissue — has no substrate in a healthy muscle. Retest window: two cardiopulmonary tests 7 days apart, which is the design that already exists. If VO2 rises by more than the test-retest error of your own lab, look for a training block before crediting the vial.

2. HbA1c and fasting insulin should move if the glucose story is systemic — and I predict they will not. The glucose-uptake mechanism is the oldest claim attached to this product and no trial has ever reported a glycemic endpoint: Ziegler measured nerve symptoms in diabetics and not their sugar control Ziegler 2009. Draw HbA1c and fasting insulin before a 12-week course and after. A fall would be a genuinely new finding; no change would establish that the insulin-like effect described in cell work does not reach whole-body glucose handling at these doses.

3. High-sensitivity CRP is where a real effect could show. The documented mechanism is anti-apoptotic and anti-oxidative Elmlinger 2011 with a described influence on the NF-kappaB pathway Machicao 2012. In somebody whose hs-CRP is genuinely elevated, a 12-week course should lower it if any of that is systemic. Retest at 12 weeks, and do not draw it within 2 weeks of an infection or a hard training block, because both move it far harder than this will.

4. Grip strength and time-to-return are the injury endpoints nobody collects. The famous use is acute muscle injury, and the outcome people care about is days lost. Grip strength is a poor proxy for a hamstring but it is the one dynamometric number a reader can actually record daily. The prediction that cuts hardest: in a randomized design with an imaging endpoint, lesion size at 2 weeks will not differ — and until somebody runs that, the elite-sport reputation of this drug rests on case selection.

What nobody has tested yet

Five experiments, ordered by how much they would change what anybody knows.

1. Nobody has published lot-to-lot compositional variability. For a product defined by a filtration step rather than a formula, the batch-to-batch mass spectrum is the specification. Five vials, one LC-MS run, one afternoon. In decades of clinical use it has never appeared, and its absence is why ‘same drug, different result’ can never be excluded when two trials disagree.

2. Nobody has run the intramuscular route in a controlled trial. Every human study is intravenous then oral Ziegler 2009 Guekht 2017 Suchkov 2022. The route that made this compound famous in football has no randomized data at all, and the 7-day oral athlete study that does exist found nothing Milovanović 2024.

3. Nobody has run it on an acute muscle tear with an imaging endpoint. Randomize 60 grade-II hamstring injuries to intramuscular Actovegin or saline, MRI lesion cross-section at 14 days, return to full training as the secondary. This is an ordinary sports-medicine trial design and the single most-used indication for this drug has never had one.

4. Nobody has tested the alpha-gal question. This is a bovine blood derivative given by injection. People sensitized to galactose-alpha-1,3-galactose after a tick bite react to mammalian products, and whether a deproteinized calf hemodialysate carries enough of that epitope to matter has never been asked in print. A specific IgE panel on 20 recipients would answer it.

5. Nobody has published a dose-response. Ziegler used 2,000 mg, ARTEMIDA 2,000 then 1,200, APOLLO 1,200. Three trials, three fixed regimens, no arm inside any of them comparing two doses. So whether the effects reported are near the top of a curve, on its rising limb, or past its peak is unknown for a drug that has treated millions of people.

Actovegin — its own safety story, not its class's

The class block is written for peptides and injectables in general. Four things here belong to this product alone.

1. It is bovine, and that is a different risk from a synthetic molecule. The hazard specific to this product is immunological: injecting material derived from another species’ blood can provoke anaphylactoid and anaphylactic reactions, and a preparation defined by a filtration cut-off rather than a formula cannot guarantee that no antigenic peptide came through. The risk is species-foreign material, not ‘injections’, and it does not shrink with experience the way a site-reaction risk does — sensitization makes the second course more dangerous than the first, not less.

2. There is a signal in the stroke data and it points the wrong way. In ARTEMIDA, recurrent ischemic stroke was the most frequently reported serious adverse event, non-significantly higher on Actovegin than on placebo Guekht 2017. The independent systematic review picked up the same thing: one included study reported a higher incidence of recurrent ischemic stroke, TIA or intracerebral hemorrhage on drug, and the review's conclusion is that benefits are uncertain and there is potential risk of harm La Fleur 2022. That is not a proven harm and it is not nothing; it is one number pointing away from the product in the largest trial it has.

3. The sourcing question a formula does not have. Because the identity of this product is a filtration cut-off applied to calf blood, its safety is downstream of herd health, and no vendor publishes the sourcing controls. That is a supply-chain question rather than a demonstrated harm, and it is the honest reason a person should prefer a licensed pharmacy product over a gray-market vial here more strongly than for a synthetic compound where an identity assay can settle the matter.

4. The failure mode is substitution, and the trial that matters found nothing. An athlete injecting this around a muscle injury has bought seven days of loading that a randomized trial showed does nothing to cardiopulmonary performance Milovanović 2024, in place of the loading progression that does. In diabetic polyneuropathy and post-stroke cognition the trials are real Ziegler 2009 Guekht 2017; in healthy sport they are absent, and the gap between those two sentences is where the money is spent.

Sources read for this page

• Machicao F, Muresanu DF, Hundsberger H, Pflüger M, Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. Journal of the Neurological Sciences 2012;322(1-2):222-227 · PMID 22910148
• Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009;32(8):1479-1484 · PMID 19470838
• Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke 2017;48(5):1262-1270 · PMID 28432265
• Suchkov IA, Mzhavanadze ND, Bogachev VY, Bokuchava M, Kuznetsov MR, Lukyanov YV, Kelimbetov R, Pang H, Araslanov SA. Efficacy and safety of Actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO). International Angiology 2022;41(5):405-412 · PMID 36264097
• Milovanović D, Radovanović D, Živković V, Srejović I, Glišić M, Jakovljević V, Scanlan A, Ponorac N, Stojanović E. The Physiological and Performance Effects of Actovegin during Maximal Cardiopulmonary Exercise Testing: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2024;16(19):3266 · PMID 39408298
• La Fleur P, Baizhaxynova A, Reynen E, Kaunelis D, Galiyeva D. Actovegin in the management of patients after ischemic stroke: A systematic review. PLoS One 2022;17(6):e0270497 · PMID 35771887
• Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular Medicine 2011;13(4):266-274 · PMID 21983748
• Kosik B, Larsen S, Bergdahl A. Actovegin improves skeletal muscle mitochondrial respiration and functional aerobic capacity in a type 1 diabetic male murine model. Applied Physiology, Nutrition, and Metabolism 2023 · PMID 37913525

Actovegin — safety, predicted from mechanism

Actovegin — interference & stacking

Bloodwork to run alongside Actovegin

Baseline first, then again at 8–12 weeks.

The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.

Check results you already have → · All 103 markers A–Z

Actovegin — frequently asked questions

Actovegin inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Actovegin is used for

Actovegin appears under 3 goals in the goal router.

Related Healing & Recovery compounds

← Explore the full Protocol Vault

↑ Back to on this page